Retatrutide vs Survodutide: Research Comparison
A Side-By-Side Research Comparison Of Retatrutide And Survodutide - next-generation multi-receptor incretin agonists in metabolic research. This Reference Compares Mechanism, Evidence Tier, Molecular Identity, And Pharmacokinetics For Qualified Researchers. For In Vitro Laboratory Research Use Only. Not Medical Advice Or Dosing Guidance.
Side-By-Side Comparison
| Retatrutide | Survodutide | |
|---|---|---|
| Category | Weight Loss & Metabolism | Weight Loss & Metabolism |
| Compound Class | Synthetic triple agonist: GIP receptor + GLP-1 receptor + glucagon receptor | Synthetic dual agonist: GLP-1 receptor + glucagon receptor |
| Evidence Tier | Investigational | Investigational |
| Molecular Target | GIPR (GIP receptor) + GLP-1R (GLP-1 receptor) + GCGR (glucagon receptor); triple incretin/glucagon signaling for maximal metabolic effect | GLP-1R (satiety, insulin secretion) + GCGR (glucagon receptor: energy expenditure, hepatic lipid metabolism); dual incretin-glucagon signaling |
| Molecular Weight | 4731.3 Da | 4231.63 Da |
| Amino Acid Sequence | 39-aa GIP/GLP-1/glucagon tri-agonist (acylated) | GLP-1/glucagon dual agonist (acylated synthetic peptide) |
| CAS Number | 2381089-83-2 | 2805997-46-8 |
| Half-Life | ~1 week | ~1 week |
| Studied For | Obesity / overweight, Type 2 diabetes, Liver fat / MASLD / NAFLD, Triple agonist weight loss | Obesity / overweight, Type 2 diabetes, MASH / metabolic liver disease, Non-alcoholic steatohepatitis (NASH) |
About Retatrutide
An investigational triple-agonist weight-loss peptide with strong early trial results.
Read The Full Retatrutide MonographAbout Survodutide
An investigational dual-agonist weight-loss and liver-disease peptide.
Read The Full Survodutide MonographKey Differences
- Primary molecular target differs: Retatrutide acts on GIPR (GIP receptor) + GLP-1R (GLP-1 receptor) + GCGR (glucagon receptor); triple incretin/glucagon signaling for maximal metabolic effect; Survodutide acts on GLP-1R (satiety, insulin secretion) + GCGR (glucagon receptor: energy expenditure, hepatic lipid metabolism); dual incretin-glucagon signaling.
Continue Researching
This Comparison Is Provided For In Vitro Laboratory Research Use Only. Not For Human Consumption, Diagnosis, Or Treatment. See The Full Research Disclaimer.